• MineHub Technologies (MHUB) has upsized its non-brokered private placement for total proceeds of up to C$2,500,000
  • The offering will now consist of up to 12,500,000 common shares
  • Proceeds will be used for general working capital purposes
  • Minehub Technologies is a technology company focused on improving efficiency in the mining and metals supply chain
  • Shares in MineHub Technologies Inc. (MHUB) are unchanged on the day, trading at C$0.26 per share at 3 pm ET

MineHub Technologies (MHUB) has upsized its previously announced non-brokered private placement for total proceeds of up to C$2,500,000.

The offering will now consist of up to 12,500,000 common shares at a price of $0.20 per share.

Arnoud Star Busmann, CEO at MineHub, remarked on the news.

“With strong demand from a very supportive shareholder base and a testament to their long-term vision, we will be increasing the amount of and removing the warrant associated with the previously announced financing.”

Proceeds will be used for general working capital purposes.

All shares issued will be subject to a statutory four-month hold period.

Minehub Technologies is a technology company focused on improving efficiency in the mining and metals supply chain.

Shares in MineHub Technologies Inc. (MHUB) are unchanged on the day, trading at C$0.26 per share at 3 pm ET.


More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.